MindMed Changes CEO? Hey Guys! What a day it has been! Today, MindMed (MMED :NEO),
(MNMD: NASDAQ), and (MMQ: FRA) has announced that JR Rahn has stepped down as CEO of MindMed effective immediately. Chief Development Officer, Robert Barrow will assume the role while MindMed is considering possible candidates.
In this episode, we’ll cover several things.
2.My general thoughts on the leadership change.
3.My thoughts on JR Rahn's successes and his departure.
4.What Robert Barrow brings to the table as CEO.
MindMed changes leadership:
Robert Barrow background:
General Reddit sentiment about MindMed's leadership change:
Expected this sub to be on fire this morning but so glad you all are cheering JR and feeling good about the next phase.
by u/ShepherdingLight in MindMedInvestorsClub
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Video editing: @themyaholy
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MNMD #MindmedNews
Have you heard about our new community?
We’re excited to announce Bonfire -
a personal growth community for people who are interested in psychedelics.
Join us for our launch event on July 18th, where we’ll share about the work we’ll be doing together to actualize our personal missions, grow, and heal together.
Psychedelic Spotlight is your reliable source for the latest stories in the emerging psychedelics industry, covering breakthrough discoveries, investor news and cultural reform.